These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 25434634)

  • 41. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse.
    Saladino E; Fleres F; Irato S; Famulari C; Macrì A
    Updates Surg; 2014 Jun; 66(2):109-13. PubMed ID: 23980020
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
    Argenta PA; Sueblinvong T; Geller MA; Jonson AL; Downs LS; Carson LF; Ivy JJ; Judson PL
    Gynecol Oncol; 2013 Apr; 129(1):81-5. PubMed ID: 23352917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study.
    Le Brun JF; Campion L; Berton-Rigaud D; Lorimier G; Marchal F; Ferron G; Oger AS; Dravet F; Jaffre I; Classe JM
    Ann Surg Oncol; 2014 Oct; 21(11):3621-7. PubMed ID: 24819120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New paradigms in the surgical and adjuvant treatment of ovarian cancer.
    Hodeib M; Eskander RN; Bristow RE
    Minerva Ginecol; 2014 Apr; 66(2):179-92. PubMed ID: 24848076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
    Lim PQ; Han IH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: a retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer.
    Marocco F; Vaira M; Milani A; Genta S; Maggiorotto F; Magistris A; Cinquegrana A; Robella M; De Simone M; Aglietta M; Ponzone R; Valabrega G
    Eur J Gynaecol Oncol; 2016; 37(5):638-643. PubMed ID: 29787001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current and future trials about HIPEC in ovarian cancer.
    Ghirardi V; Trozzi R; Scambia G; Fagotti A
    Bull Cancer; 2024 Mar; 111(3):254-260. PubMed ID: 36863924
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.
    Bakrin N; Bereder JM; Decullier E; Classe JM; Msika S; Lorimier G; Abboud K; Meeus P; Ferron G; Quenet F; Marchal F; Gouy S; Morice P; Pomel C; Pocard M; Guyon F; Porcheron J; Glehen O;
    Eur J Surg Oncol; 2013 Dec; 39(12):1435-43. PubMed ID: 24209430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
    Huo YR; Richards A; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Dec; 41(12):1578-89. PubMed ID: 26453145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?
    Cascales-Campos P; López-López V; Gil J; Arévalo-Pérez J; Nieto A; Barceló F; Gil E; Parrilla P
    Surg Oncol; 2016 Sep; 25(3):164-70. PubMed ID: 27566018
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study.
    D'Hondt V; Goffin F; Roca L; Dresse D; Leroy C; Kerger J; Cordier L; de Forges H; Veys I; Liberale G
    Int J Gynecol Cancer; 2016 Jun; 26(5):912-7. PubMed ID: 27051055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data.
    de Bree E; Helm CW
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):895-911. PubMed ID: 22845405
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
    Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
    Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
    Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
    J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women.
    Delotte J; Arias T; Guerin O; Boulahssass R; Bereder I; Bongain A; Benchimol D; Bereder JM
    Acta Obstet Gynecol Scand; 2015 Apr; 94(4):435-9. PubMed ID: 25675854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Laparoscopic HIPEC in the treatment of advanced ovarian cancer.
    Lygidakis NJ; Seretis K
    Hepatogastroenterology; 2012 May; 59(115):667-70. PubMed ID: 22469706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIPEC in advanced epithelial ovarian cancer: why is there controversy?
    Vermorken JB; van Dam P; Brand A
    Curr Opin Oncol; 2020 Sep; 32(5):451-458. PubMed ID: 32675595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience.
    Pavlov MJ; Ceranic MS; Latincic SM; Sabljak PV; Kecmanovic DM; Sugarbaker PH
    Int J Hyperthermia; 2018 Aug; 34(5):564-569. PubMed ID: 28877609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs.
    Pascual-Ramírez J; Sánchez García S; González Ruiz de la Herrán F; Villarejo Campos P; López de la Manzanara Cano C; Haya Palazuelo J; Padilla Valverde D; Martín Fernández J
    Arch Gynecol Obstet; 2014 Jul; 290(1):121-9. PubMed ID: 24488579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
    Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
    Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.